Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance.
Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, Pisters L, Ward JF, Chapin BF, Chéry L, Urkmez A, Fang AM, Higgason N, Troncoso P, Daniel CR, Logothetis C, Thompson TC, Hahn AW, Liu M, Zheng Y, Lin DW, Hanash S, Irajizad E, Fahrmann J.
Gregg JR, et al. Among authors: hahn aw.
Biomark Res. 2024 Nov 9;12(1):134. doi: 10.1186/s40364-024-00678-7.
Biomark Res. 2024.
PMID: 39522029
Free PMC article.